Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Perfil de Abivax SA



Símbolo de cotizaciónABVX

Nombre de la empresaAbivax SA

Fecha de salida a bolsaJun 26, 2015

Director ejecutivode Garidel (Marc)

Número de empleados- -

Tipo de seguridadDepository Receipt

Fin del año fiscal- -

Dirección7-11 Boulevard Haussmann

CiudadPARIS

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísFrance

Código postal75009

Teléfono33153830963

Sitio Webhttps://www.abivax.com/

Símbolo de cotizaciónABVX

Fecha de salida a bolsaJun 26, 2015

Director ejecutivode Garidel (Marc)

Ejecutivos de Abivax SA



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Kevin Shan, Ph.D.

Vice President, Global Head - Biometrics

Dr. Dominik Hoechli, M.D.

Independent Director

Ms. Nadege Briancon-Eris, Ph.D.

Senior Vice President, Global Head - Program Management

Ms. Mary Mantock

Senior Vice President, Global Head - Regulatory Affairs

Ms. Hema Keshava

Senior Vice President - Finance

Dr. Douglas Jacobstein, M.D.

Senior Vice President, Global Head - Clinical Development

Ms. Jennifer Fine

Senior Vice President, Global Head - HEOR and RWE

Mr. Kim Kelly

Chief Technical Officer

Dr. Keith Fournier, Ph.D.

Senior Vice President - Global Regulatory Affair

Dr. Maurus de la Rosa, Ph.D.

Senior Vice President - Research